Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC), pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma (CRC).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Phanes Therapeutics
- Telefonnummer: 858-766-0852
- E-post: clinical-trials@phanestx.com
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Los Angeles, California, Förenta staterna, 90033
- Rekrytering
- USC Norris Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218
- Rekrytering
- Sarah Cannon Research Institute (SCRI)
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- University of Iowa
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40202
- Rekrytering
- Norton Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Aktiv, inte rekryterande
- Dana-Farber Cancer Institute (DFCI)
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- Rekrytering
- University of Pittsburgh Medical Center (UPMC)
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- MD Anderson Cancer Center, GI Medical Oncology Dept
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- NEXT Oncology
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- Rekrytering
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria
-
18 years or older and able to sign informed consent and comply with the protocol.
-
Measurable disease as defined by RECIST V1.1 criteria for solid tumors.
-
3. Part A: Histologically or cytologically confirmed unresectable advanced or metastatic solid gastric, gastroesophageal junction (GEJ), biliary tract or pancreatic carcinomas previously treated for advanced (metastatic or unresectable) disease or for which treatment is not available or not tolerated.
Part B: Patients with PDAC and GC/GEJC must meet the same criteria as those in Part A depending on which indication and line of treatment are chosen for expansion. Patients considered 2L with BTC, without actionable genomic mutations. Patients considered 3L with CRC.
Part C, substudy C1: patients with 2L m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with Paclitaxel. Patients who are HER2 positive are eligible.
Part C, substudy C2: patients with 1L m/a PDAC will receive Spevatamig (PT886) in combination with Gemcitabine plus nab-Paclitaxel (Abraxane).
Part C, substudy C3: patients with 1L m/a PDAC will receive Spevatamig (PT886) in combination with Gemcitabine plus FOLFIRINOX/mFFX or NALIRIFOX.
Part C, substudy C4: Patients with m/a BTC without actionable genomic mutations who have progressed on 1L SOC chemotherapy (GemCis) ± ICI and are eligible for 2L SOC FOLFOX treatment.
Part C, substudy C5 and C7: Patients with CRC who are considered 3L, TAS-102 treatment naïve, eligible to receive 3L SOC TAS-102 treatment, and able to swallow oral tablets.
Part C, substudy C6 and C7: Patients with CRC who are considered 3L, and eligible to receive bevacizumab treatment, with no contraindication to bevacizumab
Part D, substudy D2: patients with m/a BTC with adenocarcinoma histology only, who are treatment naïve for their m/a disease and are eligible for treatment with SOC chemotherapy and ICI.
Part D, substudy D3: patients with 2L or 3L m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with KEYTRUDA® (pembrolizumab).
Part D, substudy D4: patients with 1L HER2 negative m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab).
-
Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (preferably fresh biopsy or if not possible, archival tissue) to be assessed for CLDN18.2 expression and other biomarkers.
-
ECOG performance status of 0 or 1.
-
Adequate organ function confirmed at screening and within 72 hours of initiating treatment.
Key Exclusion Criteria
Patients are excluded from the study if any of the following criteria apply:
- Women who are pregnant or lactating.
- Women of child-bearing potential (WOCBP) who do not use adequate birth control.
- Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- Prior CLDN18.2 or CD47 targeting therapies, or SIRPα (signal regulatory protein alpha) targeting agents.
Additional inclusion and exclusion criteria will apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Dose Escalation
An accelerated titration design will be employed for early dose levels, followed by the standard 3+3 design at higher dose levels. |
Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. |
|
Experimentell: Dose Expansion
One or more indications (GC/GEJC, BTC, CRC or PDAC) and/or lines of treatment may be selected for dose expansion at two dose levels (RDE1 and RDE2). |
Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. |
|
Experimentell: Combination Expansion with Chemotherapy or Targeted Therapy
Part C, substudy C1: patients with 2L m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with Paclitaxel. Part C, substudy C2: patients with 1L m/a PDAC will receive Spevatamig (PT886) in combination with Gemcitabine plus nab-Paclitaxel (Abraxane). Part C, substudy C3: patients with 1L m/a PDAC will receive Spevatamig (PT886) in combination with Gemcitabine plus FOLFIRINOX/mFFX or NALIRIFOX. Part C, substudy C4: patients with 2L BTC will receive PT886 in combination with SOC chemotherapy mFOLFOX6. Part C, substudy C5: patients with 3L CRC patients will receive PT886 in combination with SOC chemotherapy TAS-102. Part C, substudy C6: patients with 3L CRC patients will receive PT886 in combination with bevacizumab. Part C, substudy C7: patients with 3L CRC patients will receive PT886 in combination with SOC chemotherapy TAS-102 and bevacizumab. |
Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C1 Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: substudy C2 Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: substudy C2 Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab, Part D only) Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C3 Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudies C5 and C7. Targeted therapy as a combination partner to Spevatamig (PT886) in Part C: substudies C6 and C7. Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C3. |
|
Experimentell: Combination Expansion with KEYTRUDA® (pembrolizumab)
Part D, substudy D2: patients with 1L BTC will receive Spevatamig (PT886) in combination with KEYTRUDA® (pembrolizumab) and standard of care chemotherapy GemCis. Part D, substudy D3: patients with 2L or 3L m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with KEYTRUDA® (pembrolizumab). Part D, substudy D4: patients with 1L HER2 negative m/a GC/GEJ-C will receive Spevatamig (PT886) in combination with SOC chemotherapy and KEYTRUDA® (pembrolizumab). |
Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab, Part D only) Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D. Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab) in Part D: substudy D2 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.
Tidsram: Through study completion, an average of 2 years
|
Through study completion, an average of 2 years
|
|
To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.
Tidsram: Through study completion.
|
Through study completion.
|
|
To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.
Tidsram: Through study completion.
|
Through study completion.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
För att utvärdera farmakokinetiken för Spevatamig (PT886).
Tidsram: Genom studieens slutförande, i genomsnitt 2 år
|
Genom studieens slutförande, i genomsnitt 2 år
|
|
För att utvärdera immunogeniciteten (ADA) av Spevatamig (PT886).
Tidsram: Genom studieens slutförande, i genomsnitt 2 år
|
Genom studieens slutförande, i genomsnitt 2 år
|
|
To evaluate anti-tumor activity as assessed by additional measures other than ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.
Tidsram: Through study completion, an average of 2 years
|
Through study completion, an average of 2 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Gallvägssjukdomar
- Kolonsjukdomar
- Neoplasmer i gallvägarna
- Kolorektala neoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Kolväten
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Taxoids
- Cyklodekaner
- Gentare
- Deoxycytidin
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Platinaföreningar
- Albuminer
- Bevacizumab
- Albuminbundet paklitaxel
- Gemcitabin
- Paklitaxel
- Cisplatin
- trifluidin tipiracil läkemedelskombination
- pembrolizumab
- Folfoxprotokoll
- folfirinox
Andra studie-ID-nummer
- PT886X1101
- KEYNOTE-F58 (MK-3475-F58) (Annan identifierare: Merck Sharp & Dohme, LLC)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .